Current Status of Computer-Aided Drug Design for Type 2 Diabetes

被引:31
作者
Bibi, Shabana [1 ]
Sakata, Katsumi [1 ]
机构
[1] Maebashi Inst Technol, Grad Sch Engn, Dept Environm & Life Engn, Maebashi, Gunma 3710816, Japan
关键词
Computer-aided drug design; diabetes mellitus; FDA-approved therapeutic options; glucose level; hypoglycemia; therapeutic mechanism-based drug design; PHOSPHATASE 1B INHIBITORS; BIOMOLECULAR SIMULATION; MOLECULAR DOCKING; ACCURATE DOCKING; PHARMACOPHORE; DISCOVERY; LIGAND; OBESITY; REDUCTASE; SOFTWARE;
D O I
10.2174/1573409912666160426120709
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Background: Diabetes is a metabolic disorder that requires multiple therapeutic approaches. The pancreas loses its functionality to properly produce the insulin hormone in patients with diabetes mellitus. In 2012, more than one million people worldwide died as a result of diabetes, which was the eighth leading cause of death. Objective: Most drugs currently available and approved by the U.S. Food and Drug Administration cannot reach an adequate level of glycemic control in diabetic patients, and have many side effects; thus, new classes of compounds are required. Efforts based on computer-aided drug design (CADD) can mine a large number of databases to produce new and potent hits and minimize the requirement of time and dollars for new discoveries. Methods: Pharmaceutical sciences have made progress with advances in drug design concepts. Virtual screening of large databases is most compatible with different computational methods such as molecular docking, pharmacophore, quantitative structure-activity relationship, and molecular dynamic simulation. Contribution of these methods in selection of antidiabetic compounds has been discussed. Results: The Computer-Aided Drug Design (CADD) approach has contributed to successful discovery of novel antidiabetic agents. This mini-review focuses on CADD approach on currently approved drugs and new therapeutic agents-in-development that may achieve suitable glucose levels and decrease the risk of hypoglycemia, which is a major obstacle to glucose control and a special concern for therapies that increase insulin levels. Conclusion: Drug design and development for type 2 diabetes have been actively studied. However, a large number of antidiabetic drugs are still in early stages of development. The conventional target- and structure-based approaches can be regarded as part of the efforts toward therapeutic mechanism-based drug design for treatment of type 2 diabetes. It is expected that further improvement in CADD approach will enhance the new discoveries.
引用
收藏
页码:167 / 177
页数:11
相关论文
共 52 条
[1]   Structure-based design of anti-infectives [J].
Agarwal, Anil K. ;
Fishwick, Colin W. G. .
ANTIMICROBIAL THERAPEUTICS REVIEWS, 2010, 1213 :20-45
[2]   Identification of novel PTP1B inhibitors by pharmacophore based virtual screening, scaffold hopping and docking [J].
Balaramnavar, Vishal M. ;
Srivastava, Rohit ;
Rahuja, Neha ;
Gupta, Swati ;
Rawat, Arun K. ;
Varshney, Salil ;
Chandasana, Hardik ;
Chhonker, Yashpal S. ;
Doharey, Pawan Kumar ;
Kumar, Santosh ;
Gautam, Sudeep ;
Srivastava, Swayam Prakash ;
Bhatta, Rabi Sankar ;
Saxena, Jitendra Kumar ;
Gaikwad, Anil Nilkanth ;
Srivastava, Arvind K. ;
Saxena, Anil K. .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2014, 87 :578-594
[3]   Computationally motivated synthesis and enzyme kinetic evaluation of N-(β-D-glucopyranosyl)-1,2,4-triazolecarboxamides as glycogen phosphorylase inhibitors [J].
Begum, Jaida ;
Varga, Gergely ;
Docsa, Tibor ;
Gergely, Pal ;
Hayes, Joseph M. ;
Juhasz, Laszlo ;
Somsak, Laszlo .
MEDCHEMCOMM, 2015, 6 (01) :80-89
[4]  
Berg J.M., 2002, Oxidative Phosphorylation, V5
[5]   CHARMM - A PROGRAM FOR MACROMOLECULAR ENERGY, MINIMIZATION, AND DYNAMICS CALCULATIONS [J].
BROOKS, BR ;
BRUCCOLERI, RE ;
OLAFSON, BD ;
STATES, DJ ;
SWAMINATHAN, S ;
KARPLUS, M .
JOURNAL OF COMPUTATIONAL CHEMISTRY, 1983, 4 (02) :187-217
[6]   The Amber biomolecular simulation programs [J].
Case, DA ;
Cheatham, TE ;
Darden, T ;
Gohlke, H ;
Luo, R ;
Merz, KM ;
Onufriev, A ;
Simmerling, C ;
Wang, B ;
Woods, RJ .
JOURNAL OF COMPUTATIONAL CHEMISTRY, 2005, 26 (16) :1668-1688
[7]   The GROMOS software for biomolecular simulation:: GROMOS05 [J].
Christen, M ;
Hünenberger, PH ;
Bakowies, D ;
Baron, R ;
Bürgi, R ;
Geerke, DP ;
Heinz, TN ;
Kastenholz, MA ;
Kräutler, V ;
Oostenbrink, C ;
Peter, C ;
Trzesniak, D ;
Van Gunsteren, WF .
JOURNAL OF COMPUTATIONAL CHEMISTRY, 2005, 26 (16) :1719-1751
[8]   What has computer-aided molecular design ever done for drug discovery? [J].
Clark, David E. .
EXPERT OPINION ON DRUG DISCOVERY, 2006, 1 (02) :103-110
[9]   Recent Advances in the Discovery of Competitive Protein Tyrosine Phosphatase 1B Inhibitors for the Treatment of Diabetes, Obesity, and Cancer [J].
Combs, Andrew P. .
JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (06) :2333-2344
[10]   COMPARATIVE MOLECULAR-FIELD ANALYSIS (COMFA) .1. EFFECT OF SHAPE ON BINDING OF STEROIDS TO CARRIER PROTEINS [J].
CRAMER, RD ;
PATTERSON, DE ;
BUNCE, JD .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1988, 110 (18) :5959-5967